Cellular signal transduction by anandamide and 2-arachidonoylglycerol

Barg, 1995, Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides, Eur. J. Pharmacol., 287, 145, 10.1016/0014-2999(95)00487-4

Bayewitch, 1995, The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling, FEBS Lett., 375, 143, 10.1016/0014-5793(95)01207-U

Berdyshev, 1997, Influence of fatty acid ethanolamides and Δ9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells, Eur. J. Pharmacol., 330, 231, 10.1016/S0014-2999(97)01007-8

Berglund, 1998, Structural requirements for arachidonylethanolamide interaction with CB1 and CB2 cannabinoid receptors: pharmacology of the carbonyl and ethanolamide groups, Prostaglandins Leukot. Essent. Fatty Acids, 59, 111, 10.1016/S0952-3278(98)90089-8

Bloom, 1997, Nonclassical and endogenous cannabinoids: effects on the ordering of brain membranes, Neurochem. Res., 22, 563, 10.1023/A:1022413901857

Boger, 1998, Chemical requirements for inhibition of gap junction communication by the biologically active lipid oleamide, Proc. Natl. Acad. Sci. USA, 95, 4810, 10.1073/pnas.95.9.4810

Boger, 1999, Arachidonic acid amide inhibitors of gap junction cell-cell communication, Bioorg. Med. Chem. Lett., 9, 1151, 10.1016/S0960-894X(99)00148-1

Boring, 1996, Cerebrodiene, arachidonyl ethanolamide, and hybrid structures: potential for interaction with brain cannabinoid receptors, Prostaglandins Leukot. Essent. Fatty Acids, 55, 207, 10.1016/S0952-3278(96)90100-3

Bouaboula, 1995, Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells, J. Biol. Chem., 270, 13973, 10.1074/jbc.270.23.13973

Bouaboula, 1995, Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1, Biochem. J., 312, 637, 10.1042/bj3120637

Bouaboula, 1996, Signalling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinases and induction of Krox-24 expression, Eur. J. Biochem., 237, 704, 10.1111/j.1432-1033.1996.0704p.x

Bouaboula, 1999, Cannabinoid receptor CB1 activates the Na+/H+ exchanger NHE-1 isoform via Gi-mediated mitogen activated protein kinase signaling transduction pathways, FEBS Lett., 449, 61, 10.1016/S0014-5793(99)00395-6

Breivogel, 1998, Cannabinoid receptor agonist efficacy for stimulating [35S]GTPγS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity, J. Biol. Chem., 273, 16865, 10.1074/jbc.273.27.16865

Burkey, 1997, Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain, Eur. J. Pharmacol., 336, 295, 10.1016/S0014-2999(97)01255-7

Chataigneau, 1998, Cannabinoid CB1 receptor and endothelium-dependent hyperpolarization in guinea-pig carotid, rat mesenteric and porcine coronary arteries, Br. J. Pharmacol., 123, 968, 10.1038/sj.bjp.0701690

Chaytor, 1999, The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication, J. Physiol., 520, 539, 10.1111/j.1469-7793.1999.00539.x

Cheer, 1999, Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors, Neuropharmacology, 38, 533, 10.1016/S0028-3908(98)00208-1

Childers, 1996, Role of cyclic AMP in the actions of cannabinoid receptors, Biochem. Pharmacol., 52, 819, 10.1016/0006-2952(96)00419-4

Childers, 1994, Effects of anandamide on cannabinoid receptors in rat brain membranes, Biochem. Pharmacol., 47, 711, 10.1016/0006-2952(94)90134-1

Coffey, 1996, Tetrahydrocannabinol inhibition of macrophage nitric oxide production, Biochem. Pharmacol., 52, 743, 10.1016/0006-2952(96)00356-5

DePetrocellis, 1998, The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation, Proc. Natl. Acad. Sci. USA, 95, 8375, 10.1073/pnas.95.14.8375

Derkinderen, 1996, Regulation of a neuronal form of focal adhesion kinase by anandamide, Science, 273, 1719, 10.1126/science.273.5282.1719

Derocq, 1998, The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines, FEBS Lett., 425, 419, 10.1016/S0014-5793(98)00275-0

Deutsch, 1997, Production and physiological actions of anandamide in the vasculature of the rat kidney, J. Clin. Invest., 100, 1538, 10.1172/JCI119677

Devane, 1992, Isolation and structure of a brain constituent that binds to the cannabinoid receptor, Science, 258, 1946, 10.1126/science.1470919

DiMarzo, V., DePetrocellis, L., Bisogno, T., Maurelli, S., 1997. The endogenous cannabimimetic eicosanoid, anandamide, induces arachidonate release in J774 mouse macrophages. In: Honn (Ed.), Eicosanoids and Other Bioactive Lipids in Cancer Inflammation and Radiation Injury, vol. 3. Plenum Press, NY, pp. 341–346.

DiMarzo, 1998, Interactions between synthetic vanilloids and the endogenous cannabinoid system, FEBS Lett., 436, 449, 10.1016/S0014-5793(98)01175-2

Fan, 1995, Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons, J. Neurochem., 73, 907

Felder, 1992, Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones, Mol. Pharmacol., 42, 838

Felder, 1993, Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction, Proc. Natl. Acad. Sci. USA, 90, 7656, 10.1073/pnas.90.16.7656

Felder, 1995, Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors, Mol. Pharmacol., 48, 443

Fimiani, 1999, Morphine and anandamide stimulate intracellular calcium transients in human arterial endothelial cells: coupling to nitric oxide release, Cell. Signal., 11, 189, 10.1016/S0898-6568(98)00060-6

Fulton, 1998, Evidence against anandamide as the hyperpolarizing factor mediating the nitric oxide-independent coronary vasodilator effect of bradykinin in the rat, J. Pharmacol. Exp. Ther., 286, 1146

Gebremedhin, 1999, Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current, Am. J. Physiol., 276, H2085

Griffin, 1998, Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5′-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes, J. Pharmacol. Exp. Ther., 285, 553

Gonsiorek, 2000, Endocannabinoid 2-arachidonyl glycerol is a full agonist through human Type 2 cannabinoid receptor: antagonism by anandamide, Mol. Pharmacol., 57, 1045

Guan, 1997, The sleep-inducing lipid oleamide deconvolutes gap junction communication and calcium wave transmission in glial cells, J. Cell Biol., 139, 1785, 10.1083/jcb.139.7.1785

Guzman, 1999, Effects of cannabinoids on energy metabolism, Life Sci., 65, 657, 10.1016/S0024-3205(99)00288-X

Hampson, 1998, Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission, J. Neurochem., 70, 671, 10.1046/j.1471-4159.1998.70020671.x

Hillard, 1999, Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1), J. Pharmacol. Exp. Ther., 289, 1427

Ishac, 1996, Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves, Br. J. Pharmacol., 118, 2023, 10.1111/j.1476-5381.1996.tb15639.x

Janis, 1988, Isolation and characterization of a fraction from brain that inhibits 1,4-[3H]dihydropyridine binding and L-type calcium channel current, FEBS Lett., 239, 233, 10.1016/0014-5793(88)80923-2

Jarai, 1999, Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors, Proc. Natl. Acad. Sci. USA, 96, 14136, 10.1073/pnas.96.24.14136

Jarai, 2000, Cardiovascular effects of 2-arachidonoyl glycerol in anesthetized mice, Hypertension, 35, 679, 10.1161/01.HYP.35.2.679

Jarrahian, 1997, Arachidonylethanolamide (anandamide) binds with low affinity to dihydropyridine binding sites in brain membranes, Prostaglandins Leukot. Essent. Fatty Acids, 57, 551, 10.1016/S0952-3278(97)90559-7

Jeon, 1996, Attenuation of inducible nitric oxide synthase gene expression by Δ9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor-6B/Rel activation, Mol. Pharmacol., 50, 334

Johnson, 1993, Isolation, identification and synthesis of an endogenous arachidonic amide, Prostaglandins Leukot. Essent. Fatty Acids, 48, 429, 10.1016/0952-3278(93)90048-2

Kearn, 1999, Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange, J. Neurochem., 72, 2379, 10.1046/j.1471-4159.1999.0722379.x

Kiss, 1999, Anandamide stimulates phospholipase D activity in PC12 cells but not in NIH 3T3 fibroblasts, FEBS Lett., 447, 209, 10.1016/S0014-5793(99)00295-1

Lake, 1997, Cannabinoid-induced hypotension and bradycardia in rats is mediated by CB1-like cannabinoid receptors, J. Pharmacol. Exp. Ther., 281, 1030

Lake, 1997, Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats, Hypertension, 29, 1204, 10.1161/01.HYP.29.5.1204

Liu, 2000, Functional CB1 cannabinoid receptors in human vascular endothelial cells, Biochem. J., 346, 835, 10.1042/0264-6021:3460835

Mackie, 1993, Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells, Mol. Pharmacol., 44, 498

Mackie, 1995, Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor, J. Neurosci., 15, 6552, 10.1523/JNEUROSCI.15-10-06552.1995

McAllister, 1999, Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a Xenopus oocyte expression system, J. Pharmacol. Exp. Ther., 291, 618

Mechoulam, 1995, Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors, Biochem. Pharmacol., 50, 83, 10.1016/0006-2952(95)00109-D

Melck, 1999, Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors, Biochem. Biophys. Res. Commun., 262, 275, 10.1006/bbrc.1999.1105

Molina-Holgado, 1997, Anandamide suppresses nitric oxide and TNF-∀ responses to Theiler's virus or endotoxin in astrocytes, Neuroreport, 8, 1929, 10.1097/00001756-199705260-00027

Mombouli, 1999, Anandamide-induced mobilization of cytosolic Ca2+ in endothelial cells, Br. J. Pharmacol., 126, 1593, 10.1038/sj.bjp.0702483

Netzeband, 1999, Cannabinoids enhance NMDA-elicited Ca2+ signals in cerebellar granule neurons in culture, J. Neurosci., 19, 8765, 10.1523/JNEUROSCI.19-20-08765.1999

Niederhoffer, 1999, Involvement of CB1 cannabinoid receptors in the EDHF-dependent vasorelaxation in rabbits, Br. J. Pharmacol., 126, 1383, 10.1038/sj.bjp.0702452

Patel, 1998, Arachidonylethanolamide (AEA) activation of FOS proto-oncogene protein immunoreactivity in the rat brain, Brain Res., 797, 225, 10.1016/S0006-8993(98)00364-3

Pinto, 1994, Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid, Mol. Pharmacol., 46, 516

Plane, 1997, Evidence that anandamide and EDHF act via different mechanisms in rat isolated mesenteric arteries, Br. J. Pharmacol., 121, 1509, 10.1038/sj.bjp.0701361

Poling, 1996, Anandamide, an endogenous cannabinoid, inhibits Shaker-related voltage-gated K+ channels, Neuropharmacology, 35, 983, 10.1016/0028-3908(96)00130-X

Pratt, 1998, N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor, Am. J. Physiol., 274, H375

Prevot, 1998, Morphine and anandamide coupling to nitric oxide stimulates GnRH and CRF release from rat median eminence: neurovascular regulation, Brain Res., 790, 236, 10.1016/S0006-8993(98)00066-3

Priller, 1995, Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors, Mol. Pharmacol., 48, 288

Randall, 1996, An endogenous cannabinoid as an endothelium-derived vasorelaxant, Biochem. Biophys. Res. Commun., 229, 114, 10.1006/bbrc.1996.1766

Randall, M.D., Kendall, D.A., 1997a. Involvement of cannabinoid in endothelium-derived hyperplacizing factor-mediated coronory vasorelaxation. Eur. J. Pharmacol, 335, 205–209.

Randall, 1997, Comparative pharmacology of endothelium-derived hyperpolarizing factor and anandamide in rat isolated mesentery, Eur. J. Pharmacol., 333, 191, 10.1016/S0014-2999(97)01137-0

Sagan, 1999, Anandamide and WIN55212-2 inhibit cyclic AMP formation through G-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes, Eur. J. Neurosci., 11, 691, 10.1046/j.1460-9568.1999.00480.x

Sanchez, 1998, Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the Δ9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes, Mol. Pharmacol., 54, 834, 10.1124/mol.54.5.834

Shimasue, 1996, Effects of anandamide and arachidonic acid on specific binding of (+)-PN200-110, diltiazem and (−)-desmethoxyverapamil to L-type Ca2+ channel, Eur. J. Pharmacol., 296, 347, 10.1016/0014-2999(95)00826-8

Stefano, 1996, Cannabinoid receptors are coupled to nitric oxide release in invertebrate immunocytes, microglia, and human monocytes, J. Biol. Chem., 271, 19238, 10.1074/jbc.271.32.19238

Stefano, 1997, Morphine- and anandamide-stimulated nitric oxide production inhibits presynaptic dopamine release, Brain Res., 763, 63, 10.1016/S0006-8993(97)00403-4

Stefano, 1997, Identification and characterization of the leech CNS cannabinoid receptor: coupling to nitric oxide release, Brain Res., 753, 219, 10.1016/S0006-8993(96)01484-9

Stefano, 1998, Antagonism of LPS and IFN-( induction of iNOS in human saphenous vein endothelium by morphine and anandamide by nitric oxide inhibition of adenylate cyclase, J. Cardiovasc. Pharmacol., 31, 813, 10.1097/00005344-199806000-00003

Sugiura, 1995, 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain, Biochem. Biophys. Res. Commun., 215, 89, 10.1006/bbrc.1995.2437

Sugiura, 1996, 2-Arachidonoylglycerol, a putative endogenous cannabinoid receptor ligand, induces rapid, transient elevation of intracellular free Ca2+ in neuroblastoma×glioma hybrid NG108-15 cells, Biochem. Biophys. Res. Commun., 229, 58, 10.1006/bbrc.1996.1757

Sugiura, 1997, Is the cannabinoid CB1 receptor a 2-arachidonoylglycerol receptor? Structural requirements for triggering a Ca2+ transient in NG108-15 cells, J. Biochem., 122, 890, 10.1093/oxfordjournals.jbchem.a021838

Sugiura, 1997, Inhibition by 2-arachidonoylglycerol, a novel type of possible neuromodulator, of the depolarization-induced increase in intracellular free calcium in neuroblastoma×glioma hybrid NG108-15 cells, Biochem. Biophys. Res. Commun., 233, 207, 10.1006/bbrc.1997.6425

Sugiura, 1999, Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds, J. Biol. Chem., 274, 2794, 10.1074/jbc.274.5.2794

Szallasi, 1999, Vanilloid (capsaicin) receptors and mechanisms, Pharmacol. Rev., 51, 159

Varga, 1995, Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide, Eur. J. Pharmacol., 278, 279, 10.1016/0014-2999(95)00181-J

Varga, 1996, Mechanism of the hypotensive action of anandamide in anesthetized rats, Hypertension, 28, 682, 10.1161/01.HYP.28.4.682

Venance, 1995, Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes, Nature, 376, 590, 10.1038/376590a0

Venance, 1997, (R)-methanandamide inhibits receptor-induced calcium responses by depleting internal calcium stores in cultured astrocytes, Pflugers Arch. Eur. J. Physiol., 434, 147, 10.1007/s004240050376

Vogel, 1993, Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase, J. Neurochem., 61, 352, 10.1111/j.1471-4159.1993.tb03576.x

Wagner, 1997, Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock, Nature, 390, 518, 10.1038/37371

Wagner, 1998, Cardiovascular actions of cannabinoids and their generation during shock, J. Mol. Med., 76, 824, 10.1007/s001090050287

Wagner, J.A., Varga, K., Jaraj, Z., Kunos, G., 1998b. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 33, 429–434.

Wartmann, 1995, The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide, FEBS Lett., 359, 133, 10.1016/0014-5793(95)00027-7

White, 1997, A comparison of EDHF-mediated and anandamide-induced relaxations in the rat isolated mesenteric artery, Br. J. Pharmacol., 122, 1573, 10.1038/sj.bjp.0701546

Zygmunt, 1999, Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide, Nature, 400, 452, 10.1038/22761